Sandoz granted novel biosimilars approval
European Pharmaceutical Review
MARCH 6, 2024
Keren Haruvi, President Sandoz North America highlighted that denosumab is a medicine that can address primary and secondary bone loss, such as osteoporosis, as well as cancer-related skeletal events. The approval is also accompanied by labelling with safety warnings.
Let's personalize your content